VISION
Inspiring transformational change in the
field of oncology diagnostics
MISSION
To develop and deliver accurate, rapid, minimally
invasive oncology diagnostic products utilising our
patented MCM5 antibodies
Arquer Diagnostics is focused on the development and commercialisation of highly accurate minichromosome maintenance (MCM) protein based non-invasive tests for cancer diagnosis and monitoring.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.
Latest News
Arquer Diagnostics @Arquer Diagnostics
Earlier this month, we announced that we would be moving our #diagnostic innovation into the world of #prostatecancer detection. We have set up a #clinicalstudy for prostate cancer in ten UK #hospitals and will be looking to open a European study very soon. https://t.co/7Zn0Z96LFW
Arquer Diagnostics @Arquer Diagnostics
For many suspected of having #cancer, waiting for #results can be a challenging experience. Using #ADXBLADDER will help speed up this delicate process as our #ELISA can be run in as quickly as 2.5 hours. Find out more about ADXBLADDER by visiting our website. https://t.co/4sVRxn29i8
Arquer Diagnostics @Arquer Diagnostics
In the world of #diagnostics, #accuracy is key. #ADXBLADDER's unparalleled 99% Negative Predictive Value allows #urologists to identify cancer-negative patients with more #reliability, accuracy and #confidence than ever before. https://t.co/TGcm3u42JP
Arquer Diagnostics @Arquer Diagnostics
At #Arquer, we're highly committed to improving the lives of #bladdercancer patients and their families. To achieve this aim, we conduct all of our work with #integrity and #honesty whilst ensuring that all our employees and business partners hold true to this #value. https://t.co/bvsypc5E3n
Arquer Diagnostics @Arquer Diagnostics
With our latest #patient #study at an end, we can see results that are extremely consistent with our existing clinical #data. The consistency of our evidence and rigorous nature of our research has made it clear that #ADXBLADDER can replace #cytology in #cancerdiagnosis. https://t.co/PorHLL3LEo
